MDT logo

Medtronic

MDT · What the business does, what can go wrong, and how options sellers approach it

What it does

Medtronic is a global medical-device company. It designs and manufactures devices that treat chronic conditions, mostly in and around the heart, brain, spine and digestive system.

Its products include pacemakers, defibrillators, heart valves, stents, catheters for treating irregular heartbeats, spinal implants, neurostimulation systems and surgical tools. The company is incorporated in Ireland and sells to hospitals and physicians around the world.

How it makes money

Medtronic sells devices and related supplies to hospitals, clinics and surgical centers. Many products are implanted or used in procedures, so sales rise and fall with procedure volumes. Newer products can carry higher prices, and some come with ongoing sales of disposable components or consumables. Revenue comes from many countries, so currency moves affect reported results.

Why investors own it

  • Broad portfolio: No single product line defines the company, which can soften the impact of trouble in any one area.
  • Aging populations: Demand for cardiac, neurological and surgical care tends to grow as people live longer.
  • Dividend focus: The company has a long record of paying and raising a dividend, which appeals to income-oriented holders. Dividends are never guaranteed.
  • Switching costs: Surgeons train on specific devices, and hospitals often stay with familiar suppliers.

What can go wrong

  • Competitors may win share with newer technology in fast-moving categories.
  • Regulatory delays, product recalls or safety warnings can hurt sales and reputation.
  • Hospital budgets, reimbursement changes and pricing pressure can squeeze margins.
  • Large, complex businesses can be slow to innovate, and reorganizations or divestitures may disrupt operations.

What to watch

  • Organic revenue growth by segment
  • Procedure volumes
  • Pipeline approvals from the FDA and other regulators
  • Product recalls or safety notices

Options income angle

Options on MDT are generally liquid, especially near-the-money contracts in near-term expirations.

Implied volatility tends to rise ahead of earnings, regulatory decisions and major trial results. As a large, established company, MDT usually carries modest premiums.

One caution: an earnings surprise, recall or pipeline setback can push the stock well past a short strike, capping covered-call gains or leaving put sellers assigned after a drop.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended April 24, 2026, filed June 18, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Medtronic reported higher sales and earnings for the fiscal year ended April 24, 2026, led by its heart rhythm and ablation products. The company is also separating its Diabetes Business, a process the filing flags as complex, costly and uncertain in timing. Tariffs, a long-running Puerto Rico tax dispute and a thin cushion on one large goodwill balance are the main pressure points.

How the business did

  • Net sales were $36,364 million, up 8% from $33,537 million. Cardiovascular reached $13,976 million, up 12 percent, and Cardiac Rhythm & Heart Failure rose 17 percent on strong pulsed ablation sales (a newer way of treating irregular heartbeat). Neuroscience rose 4 percent and Medical Surgical rose 5 percent.
  • Diabetes sales were $3,112 million, up 13%, driven mainly by international demand for the MiniMed 780G system. Diabetes is no longer a reportable segment.
  • GAAP diluted earnings per share were $3.73 versus $3.61. The adjusted (non-GAAP) figure, which strips out items such as intangible amortization, was $5.53 versus $5.49. The effective tax rate rose to 21.2 % from 16.6 %.
  • Operating cash flow was $7,330 million, and free cash flow (operating cash flow minus equipment spending) was $5,426 million. The company repurchased 10 million shares versus 38 million the year before, with approximately $1.2 billion left on its authorization.
  • Cost of products sold rose partly because of $185 million of increased tariffs and duties and $84 million of asset write offs. Italy's "payback" rules for medical device spending added $39 million to net sales, versus a $90 million reduction the year before.

Risks specific to this company

  • Diabetes separation: MiniMed went public in March 2026, and Medtronic retains approximately 90% ownership. Further steps may slip or never happen, and could bring costs, leftover overhead and tax consequences. The filing notes MiniMed's stock price fell after the IPO and warns of possible future impairment charges (write-downs of asset value).
  • Puerto Rico tax case: The IRS dispute over income allocated to Medtronic's Puerto Rico manufacturing subsidiary dates to fiscal years 2005 and 2006. In September 2025 the appeals court sent it back to the Tax Court, and an adverse outcome could materially hurt results.
  • Tariffs and trade: At rates as of June 3, 2026, the company estimates a pre-tax net tariff impact of $250 million in fiscal year 2027, before any government refunds. China is approximately six percent of revenue, and its volume-based purchasing programs can force price cuts.
  • Goodwill cushion: $20.0 billion of goodwill sits in Medical Surgical, whose estimated fair value exceeded its carrying value by approximately 12%. A weaker outlook could mean a write-down.
  • Supply chain: Some components come from sole suppliers, and several key products rely on specific, capacity-constrained sterilization facilities that would take time to replace.
  • Competition and site shifts: The filing names GLP-1 drugs as an alternative to some device therapies, and bariatric procedure declines hurt Medical Surgical. Shifts toward ambulatory surgery centers also add pricing pressure.

What management is watching

  • Product adoption: Management points to the Affera and PulseSelect ablation systems, the Micra pacemaker, the Hugo surgical robot and the Stealth AXiS surgical system as key drivers.
  • Deals: CathWorks closed in April 2026 for $525 million of consideration. Scientia Vascular closed June 12, 2026 with approximately $550 million up-front. SPR Therapeutics is pending at approximately $650 million.
  • Spending: Research and development was $2.9 billion versus $2.7 billion. Selling, general and administrative expense was $11.8 billion, which included costs of preparing the Diabetes separation.
  • Separation timing: The company plans to complete the separation of its Diabetes Business within the next fiscal year.
  • Measures cited: Management points investors to non-GAAP earnings per share, the non-GAAP nominal tax rate and free cash flow. Total debt was $28.0 billion versus $28.5 billion, and credit ratings were unchanged.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended July 31, 2026, filed September 3, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Medtronic reported net sales of $9,756 million for the quarter ended July 31, 2026, up 14%. Management says an extra week in this 53-week fiscal year added an estimated $570 million to reported growth, so part of the increase is a calendar effect. Cardiac ablation (treating irregular heartbeats) led the growth, and both earnings per share and cash flow rose sharply.

How the business did

  • Profit: Diluted earnings per share were $1.14 under U.S. GAAP (standard accounting rules), versus $0.81 a year earlier. On a non-GAAP basis, which strips out items like intangible amortization and restructuring, they were $1.45 versus $1.26. A $64 million gain on minority investments, versus a $113 million loss a year earlier, helped the GAAP figure.
  • Segments: Cardiovascular rose 20%. Electrophysiology Therapies reached $2,218 million, up 30%, driven by pulsed field ablation. Neuroscience and Medical Surgical each rose 10%. The Diabetes business had sales of $843 million, up 17%. Specialty Therapies was partly held back by the Pipeline Vantage recall.
  • Costs: Cost of products sold was flat as a percentage of sales, with favorable pricing and cost-down initiatives offset by unfavorable mix. Research and development spending was $771 million versus $726 million. Selling, general, and administrative expense rose with sales growth and product launches.
  • Cash and capital: Operating cash flow was $1,793 million versus $1,088 million. Free cash flow, which is operating cash flow minus spending on property, plant, and equipment, was $1,290 million versus $584 million. The company closed the Scientia Vascular acquisition ($681 million total consideration) and the SPR Therapeutics acquisition ($654 million). It repurchased 3 million shares, with approximately $1.0 billion left under its authorization. Short-term borrowings rose by $812 million, and $450 million of commercial paper was outstanding, versus none at the prior year-end.

What management is watching

  • Diabetes separation: After the March 9, 2026 MiniMed IPO, the company retains control and plans to complete the separation of its Diabetes Business within this fiscal year. Management notes the separation may involve costs and risks as operations and infrastructure are transitioned.
  • Trade policy: Tariffs remain a flagged risk to costs. After the Supreme Court's February 20, 2026 ruling on IEEPA tariffs, the company has taken part in the refund process. The year-over-year tariff impact was not material once refunds are included.
  • Product drivers: Management points to the Affera mapping and ablation system with Sphere-9 catheter, PulseSelect, the Hugo robotic surgery system, and the AiBLE spine ecosystem, as well as its ability to meet demand and win regulatory approvals.
  • Goodwill: The Medical Surgical unit carries $19.7 billion of goodwill. In the last annual test its estimated fair value exceeded its carrying value by approximately 12%, the thinnest margin of the four reporting units.
  • Measures cited: Management directs investors to non-GAAP earnings, the non-GAAP tax rate (17.2% for the quarter), and free cash flow.

Follow MDT in Kortex

The Kortex app shows MDT's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.